PACIRA BIOSCIENCES INC (PCRX)

US6951271005 - Common Stock

26.51  +0.01 (+0.04%)

After market: 26.51 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (5/7/2024, 7:15:41 PM)

After market: 26.51 0 (0%)

26.51

+0.01 (+0.04%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.23B
Shares
PE9.08
Fwd PE9.34
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PCRX Daily chart

Company Profile

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 713 full-time employees. The company went IPO on 2011-02-03. The firm is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The firm is developing interventions to address debilitating conditions involving the sympathetic nervous system. The firm's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Company Info

PACIRA BIOSCIENCES INC

5401 West Kennedy Boulevard, Suite 890

Tampa FLORIDA 07054

P: 18135536680

CEO: David Stack

Employees: 713

Website: https://www.pacira.com/

PCRX News

News Image5 hours ago - InvestorPlacePCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024

PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image5 hours ago - BusinessInsiderPCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pacira BioSciences (NASDAQ:PCRX) just reported results for the first quarter of...

News Image10 hours ago - Pacira BioSciencesPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
News Image10 hours ago - Pacira BioSciencesPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader...

News Image18 hours ago - Pacira BioSciencesPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
News Image18 hours ago - Pacira BioSciencesPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside...

PCRX Twits

Here you can normally see the latest stock twits on PCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example